Overview

InMed is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (CBN), in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals.

In parallel to InMed’s therapeutic development programs in skin and ocular diseases, InMed is developing a cannabinoid synthesis manufacturing system called IntegraSyn^TM to produce cost-effective, pharmaceutical-grade, bio-identical cannabinoids.